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PAlliative Care in chronic Kidney diSease:
the PACKS study—quality of life, decision
making, costs and impact on carers in
people managed without dialysis
Helen Rose Noble1*, Ashley Agus2, Kevin Brazil1, Aine Burns3, Nicola A Goodfellow2, Mary Guiney2, Fiona McCourt2,
Cliona McDowell2, Charles Normand4, Paul Roderick5, Colin Thompson8, A. P. Maxwell6† and M. M. Yaqoob7†
Abstract
Background: The number of patients with advanced chronic kidney disease opting for conservative management
rather than dialysis is unknown but likely to be growing as increasingly frail patients with advanced renal disease
present to renal services. Conservative kidney management includes ongoing medical input and support from a
multidisciplinary team. There is limited evidence concerning patient and carer experience of this choice. This study
will explore quality of life, symptoms, cognition, frailty, performance decision making, costs and impact on carers in
people with advanced chronic kidney disease managed without dialysis and is funded by the National Institute of
Health Research in the UK.
Methods: In this prospective, multicentre, longitudinal study, patients will be recruited in the UK, by renal research
nurses, once they have made the decision not to embark on dialysis. Carers will be asked to ‘opt-in’ with consent
from patients. The approach includes longitudinal quantitative surveys of quality of life, symptoms, decision making
and costs for patients and quality of life and costs for carers, with questionnaires administered quarterly over
12 months. Additionally, the decision making process will be explored via qualitative interviews with renal
physicians/clinical nurse specialists.
Discussion: The study is designed to capture patient and carer profiles when conservative kidney management is
implemented, and understand trajectories of care-receiving and care-giving with the aim of optimising palliative
care for this population. It will explore the interactions that lead to clinical care decisions and the impact of these
decisions on informal carers with the intention of improving clinical outcomes for patients and the experiences of
care givers.
Keywords: Carers, Conservative kidney management, End-of-life, Mixed methods research, Palliative care, Quality of
life renal
Background
Improving quality of death and access to palliative care
is of international concern and in some countries strat-
egies to provide a dignified death in those who are dying
have been developed [1–4]. In addition there is a need to
ensure those with non-malignant disease have equitable
access to appropriate and supportive care services towards
the end-of-life [5]. The number of people living with end-
stage kidney disease (ESKD) has increased in part due to
improved access of an aging population to ESKD care but
also due to a higher prevalence of risk factors for chronic
kidney disease such as diabetes and hypertension [6, 7].
Worldwide, over 1.4 million people receive renal replace-
ment therapy [8] and the incidence is growing annually by
approximately 8 % [9]. In the UK there were 54,824 adult
patients receiving renal replacement therapy in 2013 [10].
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The mean annual cost of dialysis per patient is estimated
at £27 000 [11]. Provision of treatment for ESKD is
predicted to consume approximately 2 % of the annual
National Health Service budget [12] influenced by dispro-
portionate numbers of older, frailer, dependent patients.
Older people with advanced chronic kidney disease have
increasing prevalence of co-morbidities [13] and high
mortality with a median 2.5 life years remaining for those
over 75 years [14]. In addition treatment withdrawal
accounts for ∼ 20 % of overall deaths [15]. Evidence is
emerging that dialysis may be of little value, in terms of
survival benefit and quality of life, to some frailer patients
with multiple co-morbid conditions and poor functional
status [16, 17]. This has led to questioning of the suitabil-
ity of renal replacement therapy for ESKD in this popula-
tion [18] and the impact on quality of life [19].
ESKD includes those patients who have reached stage
5 chronic kidney disease (estimated glomerular filtration
rate ≤15 mL/min/1.73 m2 as measured using the Modifi-
cation of Diet in Renal Disease equation (MDRD) for-
mula) [20]. ESKD is a life-limiting condition associated
with substantially increased risks of morbidity and mor-
tality. The glomerular filtration may continue to fall in
patients with ESKD until a point is reached where dialy-
sis would normally be initiated to maintain life. In a
number of renal units in the UK, patients with ESKD
are offered an alternative treatment to dialysis or trans-
plantation known as conservative kidney management
where a palliative care approach is adopted and support-
ive care provided by the multidisciplinary team often in
liaison with the community team and general practi-
tioner (GP). Deciding when to withhold dialysis in this
population and provide conservative kidney manage-
ment as an alternative requires thorough ethical deliber-
ation and complex decision-making. Some patients may
not benefit form dialysis but there is limited evidence to
guide patients, carers and staff when making this im-
portant decision. There are few service models designed
to support this group and little known about how they
can be best managed. Ideally, clinicians should be able
to accurately distinguish between a patient who will do
well on dialysis and a patient who will do poorly; how-
ever, any attempt to define such a population has been
largely unsuccessful [21]. Some studies have explored
age [17], functional status [22], and comorbidity burden
[23] as predictors of survival but the development of a
criterion score to select people for dialysis has not been
developed and individualized assessment is always ne-
cessary [24]. Informing that assessment with good qual-
ity research centred on patient and carer experiences is
still required. When these complex decisions are made,
the way in which conclusions are made are difficult to
extract, teach and embed in practice. A recent thematic
synthesis of qualitative studies [25] described patients
with ESKD and their caregiver perspectives on conserva-
tive management and end-of-life care and found only
five studies [13, 26–29] offering a limited insight into
quality of life (QOL) and decision making in those man-
aged without dialysis with no exploration of changes
over time. A systematic review of conservative manage-
ment [30] identified literature in this field as widely dis-
tributed and difficult to uncover with database search
strategies. Findings were limited and preliminary in na-
ture comparing small groups of patients. Results were
not stratified by age or comorbidities and the authors
suggest that in patients who opt for non-dialytic manage-
ment of their kidney disease, guidelines are still required
to determine the best clinical practice in this area. There
appears to be no studies that explore economic aspects of
conservative management in ESKD.
Prospective, randomised trials of dialysis versus conser-
vative kidney management for ESKD are neither ethically
justifiable nor practical and therefore only observational
studies are available to inform practice [31]. A recent study
by Da Silva-Gane and colleagues [32] attempted to com-
pare QOL in patients with advanced chronic kidney dis-
ease in those opting for dialysis versus conservative kidney
management. This small study, did not investigate clinical
decision making, resource use or impact of conservative
kidney management on carers. The authors concluded that
those opting for conservative kidney management may
maintain a better QOL compared to dialysis but higher
levels of anxiety were seen in the conservative kidney man-
agement patients. The study was limited by major demo-
graphic and clinical differences between individuals and
the modality groups.
To facilitate improved decision making for individuals
with ESKD, accurate information is required for a num-
ber of issues including the expected QOL for patients
with ESKD, the potential impact a decision not to dialyse
may have on the QOL of carers; resource use and costs
of conservative care for ESKD and the factors that influ-
ence decision making from a patient/carer and health care
practitioner perspective [33–36]. Unfortunately there is a
dearth of research in this area. The present multicentre
study is designed to capture patient and carer profiles
when conservative kidney management is implemented
and to understand the trajectories of care-receiving and
care-giving. It will explore the interactions that lead to
clinical care decisions and the impact of these decisions
on carers with the intention of improving clinical out-
comes for patients and the care giver experience. The eco-
nomic analysis of conservative kidney management will
facilitate greater transparency in relation to resource allo-
cation processes for persons with chronic kidney disease.
The purpose of this article is to describe the design of the
present study and inform others on the possibilities of
performing end-of-life care research in advanced chronic
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kidney disease. The prospective and longitudinal nature of
the design will be discussed. In addition the explanation of
the methodology will serve as a comprehensive orienta-
tion for the methods section of publications arising from
the research.
The aim of the study is to measure and describe longitu-
dinally QOL, symptoms, cognition, frailty and performance
in persons with ESKD being managed without dialysis and
the impact of these issues on their carers. In addition, the
study will analyse decision making related to conservative
care for ESKD together with the costs of conservative kid-
ney management.
Study objectives
Patient focused
 To measure and describe longitudinally patient
reported outcomes including QOL, satisfaction in
decision-making and costs in patients receiving
conservative kidney management (palliative care).
 To measure and describe longitudinally changes in
cognition, frailty and performance in patients
receiving conservative kidney management
 To measure and describe the associated health and
social care costs of patients receiving conservative
kidney management.
Carer focused
 To measure and describe longitudinally QOL for
carers of patients receiving conservative kidney
management.
 To measure and describe the subjective and
objective burden of providing informal care in
carers, loss of earnings and the opportunity costs
of providing such care
Renal physicians/clinical nurse specialist focused
 To explore the decision making process that precedes
referral for conservative kidney management in
relation to patient satisfaction in decision making.
Methods/Design
The research study is a Post-Doctoral Fellowship funded
by the National Institute of Health Research in the UK.
It is a mixed method study and includes quantitative and
qualitative components [37]. In the quantitative compo-
nent a longitudinal survey of QOL, symptoms, cognition,
frailty, performance, satisfaction with decision-making,
health service use of patients and associated costs, subject-
ive burden and QOL of carers, loss of earnings and the
opportunity cost of providing informal care will be ex-
plored. In the qualitative component the decision making
process with patients and carers that precedes referral to
conservative kidney management will be explored with
renal physicians and/or clinical nurse specialists in relation
to patient satisfaction in decision making. The longitudinal
nature of the study will be explained to participants. Some
people may change their mind regarding their selected
treatment option and commence dialysis although this
is unusual in clinical practice. If this happens the patient
and carer data will continue to be collected in order to
examine how QOL might increase or decrease with a
switch of modality.
The study is multicentre across ten sites in Northern
Ireland, England and Scotland. Each site offers conserva-
tive management as a treatment option to patients who
have reached ESKD. All patients who make the decision
not to embark on dialysis will be approached to take
part in the study. Their main carer will be asked to ‘opt-
in’ to the study with the patient’s consent.
Study approvals
The study protocol has been approved by the Office for
Research Ethics Committees Northern Ireland (ORECNI)
(REC reference 14/NI/0057; 14 May 2014) and research
governance approval has been granted by the five Health
and Social Care Trusts in Northern Ireland and three acute
hospital trusts in England, UK with two others in progress
in London, England and Glasgow, Scotland. The study is
registered with the International Standard Randomised
Controlled Trial (ISRCTN) (ISRCTN06857980) [38]. It is
sponsored by Queens University Belfast and the Western
Health and Social Care Trust, and has been adopted by the
Northern Ireland Clinical Research Network (Renal). It is
supported by the Northern Ireland Clinical Trials Unit, a
UK Clinical Research Collaboration registered clinical trials
unit.
Study population
Patients
To be eligible for recruitment into the study patients
must be aged 18 years or older; have reached stage 5
chronic kidney disease with estimated glomerular filtra-
tion rate ≤15 mL/min/1.73m2as measured by the MDRD
formula [20]; and have made a confirmed decision for
conservative kidney management, i.e. management with-
out dialysis or other renal replacement therapy. Patients
lacking capacity to give consent to participate will be ex-
cluded. Capacity for consent to participate will be assessed
in collaboration with the supervising nephrologists. Non-
English speaking patients or those who do not adequately
understand verbal or written information will be excluded.
Carers
To be eligible for recruitment into the study participants
must identify as the primary carer for the patient who has
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made a confirmed decision for conservative kidney man-
agement. They must be over 18 years and the patient must
agree that the carer can be approached to participate.
Carers can only participate in the study if they ‘opt in’ to
study by making contact with the Research Nurse. Carers
who lack capacity to give consent to participate in the
study will be excluded. Non-English speaking carers will
also be excluded.
Renal physicians/clinical nurse specialists
Renal physicians and clinical nurse specialists (CNS) re-
cruited to the study must have experience of managing
clinical consultations with patients who have stage 5
chronic kidney disease and are opting for conservative
kidney management. Those clinicians and nurses with-
out experience of managing consultations with patients
who opt for conservative kidney management and who
are not nephrologists or renal nurses will be excluded.
Recruitment
Patients
Recruitment will take place over 18 months and data
collection will continue for another 12 months or until
death. The initial treatment decision is made in clinic
with a renal physician or a CNS. Once the decision is
made Research Nurses at each site will liaise with renal
physicians or CNS and use the inclusion/exclusion cri-
teria to identify potential participants. All patients across
the ten study sites who have made a decision not to
initiate dialysis and meet the study inclusion criteria will
be sent written information about the study (see Fig. 1).
They will be contacted to see if they are willing to take
part in the study. If willing to participate written in-
formed consent will be obtained at their next clinic visit
(Baseline). This should take place within 3 months after
the initial decision not to embark on dialysis.
If patients wish they can complete questionnaires them-
selves, with the nurses or with their carers. The way in
which the data are captured (self-completion or help from
staff member or carer) will be noted on the front sheet of
the questionnaires.
Carers
With the patient’s agreement, and if the patient is happy
for the carer to participate in the study, information will
be sent to the patient to give to their carer. Carers will
be asked to contact the Research Nurse if they are inter-
ested in ‘opting-in’ to the study. If a carer is interested in
participating they will be invited to attend the patient’s
next clinic appointment so that informed consent can be
obtained and baseline data collected (see Fig. 1). If the
carer is unable to attend this clinic visit then the Re-
search Nurse will send a consent form and baseline data
collection tools to their home. The carers will be asked
to return the consent form to the hospital. Information
on how to complete the tools will be given over the tele-
phone. Carers can either complete the tools themselves
or with the assistance of a Research Nurse.
Renal physicians/clinical nurse specialists
Renal physicians and CNS from each of the ten study
sites who fulfil the inclusion criteria will be identified
through the lead nephrologists or senior renal managers
for each study site. The renal physicians and CNS will be
invited to take part in a semi-structured qualitative inter-
view, conducted to explore their experience of counselling
a patient who ultimately declines dialysis (see Fig. 1). They
will be approached by the Chief Investigator of the study
via email. Written informed consent will be obtained prior
to the interview taking place. Recruitment will continue
until data are saturated [39].
Sample size
The primary outcome is to measure the true mean QOL
at 3 months using the EQ-5D-5L Visual Analogue Scale
(EQ-VAS). The EQ-VAS asks patients to place their health
on an interval scale from 0–100 where 0 is the worst state
they can imagine and 100 is the best. Using a standard de-
viation estimate of 18 from a similar study (Nephrol Dial
Transplant (2004) 19: 1594–1599),with 100 individuals in
our sample we would calculate a 95 % confidence interval
for the true mean which would be of width 7.2 units, i.e.
95 % of the time we would estimate the true mean within
plus or minus 3.6 units. With an estimated death/dropout
rate at 3 months of 10 %, a total of 112 patients are re-
quired. For the exploratory qualitative interviews with ne-
phrologists and CNS, in order to achieve data saturation
when no new patterns emerge, a sample of approximately
15–20 will be recruited until data saturation reached [39].
User involvement
The proposal has been developed in collaboration with
members of the Kidney Research and Education Initia-
tive (KREI), established in 2010 to broaden collaborative
working between renal research groups and renal educa-
tion teams to ensure involvement with patients, carers,
academics, clinicians and researchers [40]. In addition,
we collaborated with the Northern Ireland Kidney Pa-
tient Association (a self-help group run by patients with
ESKD and their carers) to help set the study aims and
objectives. All those involved in this research proposal
have personal knowledge and experience of kidney dis-
ease and offer differing perspectives to the research
team. Regular feedback meetings will be arranged on the
progress of the research for comment and scrutiny with
a particular focus on ethics, documentation (for example
in questionnaires, and information leaflets) and method-
ology. This shared decision-making will strengthen the
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partnership between patients, clinicians and researchers
involved in the research. Several of the questionnaires
were reviewed by members of the Northern Ireland Kid-
ney Patient Association and they provided constructive
feedback on feasibility of the study to the research team.
The data collection tools were then piloted with 5 pa-
tients and 5 carers aged over 70 years attending a renal
clinic to test for their clarity, ease of use and time burden.
Minor changes were made to the tools to be used to
collect economic information from patients and carers.
All patients, carers, renal physicians and CNS will have
the right to withdraw from the study at any time.
Data collection
Patients
At baseline the research nurse will collect patient demo-
graphics through a review of clinical records at study
entry (Table 1). Data collected will include age, gender,
Assessed for eligibility
Patients (n=112)
Carers (n= up to 112)
Renal physicians/clinical nurse 
specialists (n=15-20)
Inclusion criteria
Patients:
• Stage 5 chronic kidney disease with estimated 
glomerular filtration rate  15 mL/min/1.73m2
MDRD) formula.
• A confirmed decision for conservative 
management, i.e. management without dialysis 
or other renal replacement therapy. The 
decision for conservative kidney management 
will be confirmed with the nephrologist 
responsible for each patient.
• Aged over 18 years.
• Able to speak English 
Carers:
• Primary carer for patient with stage 5 chronic 
kidney disease who has made a confirmed 
decision for conservative kidney management 
as agreed with clinicians.
• Aged over 18 years.
• Patient has agreed that the carer can be 
approached to participate.
• Able to speak English
• ‘Opted in’ to study
Consultant nephrologists/CNS
• Experience of managing clinical consultations 
of patients with stage 5 chronic kidney disease 
who opt for conservative kidney management.
• Employed in the renal specialty
Patients over 12 
months
3-monthly KDQOL-
36™ Survey
EQ-5D-5L
POS-S Renal
6-monthly
DCS
Ongoing
Patient Service Use
Log
Renal 
Physicians/CNS
One exploratory 
qualitative interview 
with Principal 
Investigator
Carers over 12 
months
3-monthly
EQ-5D-5L
EQ-5D-5L by proxy
Carer questionnaire
6-monthly
DCS by proxy
Fig. 1 CONSORT diagram showing the flow of participants through each stage of study
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ethnicity (using UK Office for National Statistics cat-
egories), marital status, disease severity (as measured by
eGFR) and primary renal disease; comorbidity using the
Davies Comorbidity Score. Information will also be ob-
tained on smoking habits of the patient, their diabetes
status and on the presence or absence of vascular disease
(ischaemic heart disease, angina, myocardial infarction, per-
cutaneous coronary intervention, coronary artery bypass
graft, peripheral vascular disease and cerebrovascular acci-
dents). Biochemical data at time of entry to the study will
be recorded including serum creatinine, albumin, calcium,
phosphate, parathyroid hormone, alkaline phosphatase,
liver function tests, haemoglobin level and urine protein
creatinine ratio. The research nurse will also be asked to
document a ‘Yes’ or ‘No’ answer to the question, ‘would you
be surprised if the patient dies within 6 months?’ They will
Table 1 Schedule of Assessments
Table 1 Screening Visit (1) Visit (2) Visit (3) Visit (4)
Baseline 3 months 6 months 9 months 12 months
PATIENT
Informed Consent X
Inclusion/Exclusion Criteria X
Demographic Data X
Detail from patient’s hospital notes on who made decision
to accept CM
x
Davies Comorbidity Score x x x x x
9-point Clinical Frailty Scale x x x x x
6 Item Cognitive Impairment Test (6CIT) x x x x x
Functional performance using the PPS x x x x x
KDQOL x x x x x
EQ-5D-5L x x x x x
POS-S Renal x x x x x
DCS x x x
Patient Service Use Log x x x x x
Serum creatinine, albumin, calcium, phosphate, parathyroid
hormone, alkaline phosphatase and haemoglobin level
x x x x x
Urine protein creatinine ratio x x x x x
Liver function tests x x x x x
Smoking habits of patient x x x x x
Smoking habits of other people living in household x x x x x
Diabetes and diabetic comorbidity check x x x x x
Check for Ischemic heart disease, angina, myocardial infarction,
percutaneous coronary Intervention, coronary artery bypass graft,
peripheral vascular disease, cerebrovascular accidents in all patients.
x x x x x
Answer question ‘Would you be surprised if patient dies within
6 months?
x x x x x
CARER
Informed Consent x
Inclusion/Exclusion Criteria x
EQ-5D-5L x x x x x
EQ-5D-5L for the patient by the carer (i.e. by proxy) x x x x x
DCS x x x
Carer baseline questionnaire x
Follow up carer questionnaires x x x x
RENAL PHYSICIAN/ CLINICAL NURSE SPECIALISTS At one point during study
Qualitative interview
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also complete the 9-point Clinical Frailty Scale, 6 item Cog-
nitive Impairment Test (6CIT) and Palliative Performance
Score (PPS). Detail from patients’ hospital notes will be col-
lected on who made the decision to accept conservative
management. The Decisional Conflict Scale (DCS) will be
completed at baseline and 6 monthly (see Table 2).
Carers
At baseline and 3-monthly for 12 months, carers will be
asked to complete, the EQ-5D-5L whilst the patient is
included in study or 3 months after death of patient or
study end; the EQ-5D-5L for the patient by proxy and a
questionnaire to measure the subjective and objective
burden of providing care, loss of earnings and the op-
portunity costs of providing care. The DCS will be com-
pleted at baseline and 6 monthly (see Table 2).
Renal physicians/clinical nurse specialists
Exploratory semi-structured qualitative interviews with
consultant nephrologists and CNS will be undertaken by
the Chief Investigator over the period of the study to ex-
plore the decision making process that precedes referral
to conservative kidney management in relation to pa-
tient satisfaction in decision making. Questions can be
viewed in Table 3.
Outcome measures
The primary outcome of the study is QOL of patients at
3 months measured using the EQ-VAS.
The range of data collection tools can be viewed in
Table 2
Secondary outcome measures
Patients
 Changes in QOL, symptoms, anxiety and depression
in patients using the Kidney Disease QOL (KDQOL)
tool, EQ-5D-5L (which includes the EQ-VAS) and
Palliative Outcome Scale - Symptoms (POS-S) Renal
3-monthly over 12 months
 Changes in cognition and frailty status in patients
using the 6 Item Cognitive Impairment Test (6CIT)
and the 9-point Clinical Frailty Scale 3-monthly
over 12 months
 Changes in Performance in patients using the Palliative
Performance Scale (PPS) 3-monthly over 12 months
 Patient Satisfaction in Decision Making using the
Decisional Conflict Scale (DCS) at baseline
 Measurement of health and social care costs of
patients receiving conservative kidney management
using a Patient Service Use Log 3-monthly over
12 months
 Calculation of the number (%) of patient deaths
3-monthly and time to death.
Table 2 Data collection tools for PACKS study
Tools for use with patient
Kidney Disease QOL-36™ Quality of life of patients will be measured using
the Kidney Disease QOL-36™ Survey (KDQOL) [48], a well validated tool
in kidney disease which has demonstrated good test-retest reliability on
most dimensions (includes general health, activity limits, ability to
accomplish desired tasks, energy level, and social activities). Symptoms and
problems will also be assessed (questions 17–28) and include items about
how bothered a respondent feels by sore muscles, chest pain, cramps,
itchy or dry skin, shortness of breath, faintness/dizziness, lack of appetite,
feeling washed out or drained, numbness in the hands or feet and nausea.
Anxiety and depression will also be assessed using the KDQOL-36™ and is
measured within the mental component of the tool (questions 1–12).
EQ-5D-5L The EQ-5D [49] is the National Institute of Health and Clinical
Excellence’s (NICE) preferred method of measuring health effects in
economic evaluations and it has shown to be a valid instrument for the
measurement of health status in renal patients. The use of the new 5
level version, EQ-5D-5L, is also advocated by NICE. It consists of a
descriptive system and a visual analogue scale. The EQ-5D-5L will
be self-completed by the patients or the Research Nurse and also
completed for the patient by the carer (i.e. by proxy). The inter-rater
agreement can then be assessed.
POS-S Renal The POS-S Renal was developed in 2011 and is used as a
tool to monitor progress in individual symptoms. It is a brief tool,
primarily aimed at patients with advanced disease [50].
6 Item Cognitive Impairment Test (6CIT) The 6 Item Cognitive Impairment
Test (6CIT) Kingshill Version 2000® was developed in 1983 [51] and is a
useful dementia screening tool in Primary Care. The tool will be used to
identify cognitive impairment and changes over time during the course
of the study.
9-point Clinical Frailty Scale Frailty will be studied using the 9-point
Clinical Frailty Scale [52]. The Clinical Frailty Scale© has performed better
than measures of cognition, function or comorbidity in assessing risk for
death.
Palliative Performance Scale (PPS) The Palliative Performance Scale [53]
uses five observer-rated domains correlated to the Karnofsky Performance
Scale (100–0). The PPS is a reliable and valid tool and correlates well with
actual survival and median survival. It has been found useful for purposes
of identifying and tracking potential care needs of palliative care patients,
particularly as these needs change with disease progression.
Decisional Conflict Scale (DCS) This will be used to explore satisfaction
with decision making from a patient perspective. The scale measures
uncertainty and difficulties in the decision making process [54]. The 16
item version measures four domains: a) uncertainty in choosing options;
b) unsupported in decision making; c) feeling informed; d) decision
is consistent with values. The instrument demonstrates satisfactory
reliability and good construct validity [55]. It has been used extensively
in the United Kingdom. It will be used with patients at baseline, 6 and
12 months.
Patient Log Questionnaires have been developed using items from the
Annotated Cost Questionnaire [56] and the iMTA Valuation of Informal
Care Questionnaire [57]. These will measure healthcare resource
utilisation (and associated costs) by patients.
Tools for use with carer
EQ-5D-5L Carer quality of life will be measured using the EQ-5D-5L
detailed above. Carers will also use the EQ-5D-5L to assess the patient’s
quality of life.
Decisional Conflict Scale (DCS) Carers views on the patient’s Satisfaction
with Decision Making will also be explored using the DCS. It will be
used with patients and carers at baseline and at 6 months.
Carer questionnaire Care-related costs to carers using questionnaires will
be captured whilst patient included in study or study end. Cost
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Carers
 Carer observation of patient’s Satisfaction in
Decision Making using the Decisional Conflict Scale
(DCS) at baseline
 Changes in QOL of carers using the EQ-5D-5L and
Carer QOL 3-monthly over 12 months
 Carers assessment of patient QOL using the EQ-5D-5L
by proxy 3-monthly over 12 months
 Subjective and objective burden of providing
informal care in carers, loss of earnings and the
opportunity costs of providing informal care using
items from the iMTA Valuation of Informal Care
Questionnaire 3 monthly over the 12 months.
Renal physicians/clinical nurse specialists
 Exploration of the decision making process that
precedes referral to conservative kidney
management in relation to patient satisfaction with
renal physicians/CNS via exploratory qualitative
interviews.
The range of data collection tools can be viewed in
Table 2
Quantitative data analysis
Descriptive statistics will be used to summarise baseline
demographics and the questionnaire data from patients
and carers.
Primary outcomes
The mean and 95 % CI for the EQ-VAS will be calculated.
Additional exploratory analyses will be used to compare
the mean EQ-VAS at 3 months between categories of cat-
egorical variables (such as gender, marital status comor-
bidity) using ANCOVA adjusting for baseline scores. The
association between EQ-VAS nd other continuous vari-
ables will be investigated using simple linear regression
with EQ-VAS at 3 months as the dependent variable. Mul-
tiple linear regressions will also be used to investigate as-
sociations with comorbidities, age, gender, marital status,
severity of symptoms and depression to allow adjustments
for confounding. As the study is not powered to detect
statistically significant differences in EQ-5D-5LVAS all re-
sults will be interpreted with caution. Statistical signifi-
cance will be assumed for P values 0.05.
Secondary outcomes
Descriptive summaries of patient and carer question-
naire data at 3, 6, 9 and 12 months will be tabulated and
presented graphically where appropriate. The number
(%) of deaths at 3, 6, 9 and 12 months will be tabulated.
Time to death data will be investigated using Kaplan
Meier curves. The log rank test statistic will be used to
compare categorical variables and Cox proportional haz-
ards model for continuous variables where appropriate.
Qualitative data analysis
In the exploratory qualitative aspect of the study, coding
of qualitative data (renal physician/CNS interviews) will
be assisted with the use of NVivo version 10, qualitative
software to organise, store and retrieve data [41]. Renal
physician/CNS interviews will be recorded by the re-
searcher using a digital recorder and subsequently profes-
sionally transcribed by a transcription company previously
employed to do similar work. Electronic versions of diary
transcripts will be saved and imported into the software
programme to enable computer-assisted coding analysis.
Table 2 Data collection tools for PACKS study (Continued)
measures will include caregiver’s lost income and out-of-pocket
expenditures for formal care-giving services.
Renal Clinicians/CNS
Qualitative interviews Individual semi-structured interviews with renal
physicians/CNS will focus on the decision making process with patients
and carers that precedes referral to conservative kidney management.
Experiences of physicians related to counselling a patient who makes
the decision not to commence dialysis will be captured (For interview
guide based on the Decisional Conflict Scale (DCS) (see Table 3)
Table 3 Interview guide for qualitative interviews with renal
physicians/clinical nurse specialists
Do you feel your patients know what treatment options are available to
them?
Do you think they know the benefits of each option?
Do you think they know the risks and side effects of each option?
Do you think they are clear about which benefits matter most to them?
Do you think they are clear about which risks and side effects matter
most to them?
Do you think they are clear about which is more important to them
(the benefits or the risks and side effects).
Do you think they have enough support from others to make a choice?
Do you think they choose without pressure from others?
Do you think they have enough advice to make a choice?
Do you think they are clear about the best choice for them?
Do you think they feel sure about what to choose?
Do you think the decision is easy for them to make.
Do you think they feel they make an informed choice?
Do you think their decision shows what is important to them?
Do you expect them to stick with their decision?
Do you think they are satisfied with their decision?
What guidelines/decision tools do you use with your patients when
helping them make treatment decisions?
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This iterative process will be guided by an approach de-
scribed by de Wet and Erasmus [42]. Their approach
draws on grounded theory techniques including first level
coding and pattern coding and the development of rela-
tionships in the data.
Economic evaluation
A partial economic evaluation in the form of a cost-
outcome description of conservative kidney management
will be performed. Each patient’s health and social care
resource use and quality of life measurements over the
12 month study period will be collected as stated under
Data Collection. Unit costs will be applied to the quan-
tity of resource use for each patient and these will be ob-
tained from national sources where possible. Utilities for
the calculation of quality adjusted life years (QALYs) will
be obtained using responses on the EQ-5D-5L.
Care-related costs for the carers will also be explored.
Multiple regression methods will be used to examine pa-
tient and carer factors which are potentially associated
with their costs and to adjust for potential confounders.
Although the cost effectiveness of conservative kidney
management compared with dialysis cannot be established
within the current single arm study design, the estimation
of the costs and outcomes of conservative kidney manage-
ment will allow comparisons to be made with similar esti-
mates for dialysis already in the literature.
Study quality, monitoring and ethical considerations
To ensure the research quality and data is of a high stand-
ard rigorous study conduct and monitoring procedures will
be undertaken to ensure any problems are identified and
managed. Regular Trial Management Group meetings with
the Northern Ireland Clinical Trials Unit have taken place
and will continue and an Advisory Group of experts has
met on two occasions and will continue to meet through-
out the course of the study. Formal monitoring of study
procedures will take place at least once per year over the
course of the study at each site and as required.
Some patients in the study will be close to death. All
attempts will be made to ensure the best interests of pa-
tients and carers are taken into account. Permission to
gain access to patients will first be sought from staff.
There is the potential for patients and carers to feel co-
erced into the study due to the status of the research
nurses who are assisting with recruitment and data col-
lection. This could intimidate participants into agreeing
to participate in the study [43]. One way of attempting
to shift some of the power differentials is to explain hon-
estly to patients and carers that their care will not be
compromised if they do not agree to be involved in the
study and it is entirely their decision. It will be necessary
to look for signs of fatigue or discomfort and to curtail
any assessments as necessary. Consideration will also
need to be given to issues such as the length of assess-
ment and time of day when it takes place. Information
(written and oral) will need to take into account cognitive
abilities and participants’ preferred way of assimilating
information and may need to be adapted appropriately
e.g. some patients may need to be spoken to slowly or
need certain words explained. One view of dying people is
that they are in need of protection and should not be
approached to be involved in research [44]. An alternative
view is that everyone, whether dying or not should make
the choice for themselves. Throughout the study patients
will be fully informed regarding the research process in
order to make appropriate decisions and retain the right
to withdraw at any time without care being compromised.
Discussion
This study has been designed to explore QOL, symptoms,
cognition, frailty, performance, decision making, costs and
impact on carers in people managed without dialysis. Lit-
tle is known about QOL in those with ESKD who accept
conservative kidney management. In addition, there is
limited information on this group related to changes in
symptoms, frailty and cognition over time. The study
will also explore satisfaction with decision making for
patients and the costs of this conservative kidney care
programme. The impact on carers is virtually unknown.
The present study involves an under researched group
particularly in relation to their QOL experiences, symp-
tom burden and changes in symptoms over time. Al-
though usually a frail group with limited life expectancy
[45] cognition, frailty and performance are also poorly
explored in this population.
Davison [46] has described the methodological chal-
lenges for end-of-life research in patients with chronic
kidney disease and highlighted the difficulties of retrospect-
ive research which draws on limited, routinely collected
data. Prospective designs allow for additional collection of
patient-derived measures using questionnaires. A prospect-
ive design, as in the present study, allows for observation
of the end-of-life experience and possible dying process.
To date, many studies exploring the end-of-life experience
have relied on cross-sectional or retrospective designs
although the importance of prospective, longitudinal re-
search in those with chronic disease has been promoted
[47]. The identified sample size and the involvement of ten
study sites will help improve reliability and generalisability
of the findings. In addition the costs associated with con-
servative management end-of-life care in ESKD, previously
unexplored [46], will be investigated. To support trans-
lation of findings from the study to clinical practice,
dissemination to relevant health professionals and user
groups will take place via national and international
conference presentations and publication in high impact
peer-reviewed journals.
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The key contribution of this study will be an assess-
ment of the needs of patients (and carers) managed
without dialysis. Findings from this study can lead to de-
velopment of new healthcare policies and embedded
within clinical practice once supportive interventions have
been tested and evaluated. Patients will benefit as more ac-
curate information on conservative kidney management,
including the predicted QOL without dialysis, can be pro-
vided in the counselling process as patients make treatment
decisions. Impact on carers will be acknowledged as a first
step in developing a health-improvement programme for
carers of this patient group. Associated costs of conserva-
tive kidney management will be identified allowing for
comparison with other ESKD treatment modalities. In the
proposed project, knowledge transfer to a broader audience
will be facilitated by various mechanisms including carer
and user organisations and clinically based staff. The
protocol has been developed with clinicians, users and
carers with a key benefit of strengthening links between
researchers, practitioners, policy makers and voluntary
sectors to ensure new knowledge is translated into prac-
tice. These links will be developed and utilised to dissem-
inate the results of the proposed programme of research,
to raise awareness of developments and research priorities
in renal care and end-of-life practice.
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